BridgeBio Pharma reported strong financial results and commercial progress for the fourth quarter and full year 2024. The company's ATTR-CM treatment, Attruby (acoramidis), has gained significant traction since FDA approval in November 2024, with 1,028 unique prescriptions written by 516 prescribers as of February 17, 2025. It also secured approval in the EU under the name BEYONTTRA in February 2025, triggering a $75 million milestone payment and tiered royalties starting in the low-thirties percent.

Attruby demonstrated a 59% hazard reduction in all-cause mortality and first cardiovascular-related hospitalization in variant ATTR-CM patients, marking the strongest statistical benefit observed in this aggressive disease population. The company expects additional regulatory milestones in the first half of 2025, including Japan's approval, contributing to $105 million in anticipated milestone payments.

BridgeBio ended the quarter with $681 million in cash, cash equivalents, and short-term restricted cash, reinforcing its financial position as it advances its pipeline. Three global registrational studies—FORTIFY (BBP-418 for LGMD2I/R9), CALIBRATE (encaleret for ADH1), and PROPEL 3 (infigratinib for achondroplasia)—are fully enrolled, with last participant visits expected before the end of 2025.

CEO Neil Kumar emphasized Attruby’s differentiated efficacy and industry-leading patient support programs, which are expected to drive further adoption. The company is also progressing with its broader pipeline, aiming for first-in-class approvals for BBP-418, encaleret, and infigratinib in their respective indications.

Looking ahead, BridgeBio remains focused on expanding access to its approved therapies while advancing key pipeline programs, with multiple regulatory and clinical milestones anticipated in 2025.